Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

Similar articles for PubMed (Select 12110143)

1.

The paradigm of IL-6: from basic science to medicine.

Naka T, Nishimoto N, Kishimoto T.

Arthritis Res. 2002;4 Suppl 3:S233-42. Epub 2002 May 9. Review.

2.

IL-6/IL-6 receptor system and its role in physiological and pathological conditions.

Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M.

Clin Sci (Lond). 2012 Feb;122(4):143-59. doi: 10.1042/CS20110340. Review.

PMID:
22029668
3.

[Advances in interleukin-6 therapy].

Ogata A, Nishimoto N, Yoshizaki K.

Rinsho Byori. 1999 Apr;47(4):321-6. Review. Japanese.

PMID:
10340005
4.

IL-6 and Crohn's disease.

Ito H.

Curr Drug Targets Inflamm Allergy. 2003 Jun;2(2):125-30. Review.

PMID:
14561164
5.
6.

Interleukin 6 and its receptor: ten years later.

Hirano T.

Int Rev Immunol. 1998;16(3-4):249-84. Review.

PMID:
9505191
7.

Principles of interleukin (IL)-6-type cytokine signalling and its regulation.

Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F.

Biochem J. 2003 Aug 15;374(Pt 1):1-20. Review.

8.

gp130 and the IL-6 family of cytokines: signaling mechanisms and thrombopoietic activities.

Nakashima K, Taga T.

Semin Hematol. 1998 Jul;35(3):210-21. Review.

PMID:
9685167
9.

Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.

Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y.

Int Immunopharmacol. 2005 Nov;5(12):1731-40.

PMID:
16102523
10.

Shc mediates IL-6 signaling by interacting with gp130 and Jak2 kinase.

Giordano V, De Falco G, Chiari R, Quinto I, Pelicci PG, Bartholomew L, Delmastro P, Gadina M, Scala G.

J Immunol. 1997 May 1;158(9):4097-103.

PMID:
9126968
11.

Interleukin-6 as a key player in systemic inflammation and joint destruction.

Fonseca JE, Santos MJ, Canhão H, Choy E.

Autoimmun Rev. 2009 Jun;8(7):538-42. doi: 10.1016/j.autrev.2009.01.012. Epub 2009 Feb 2. Review.

PMID:
19189867
12.
14.

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

Jones SA, Scheller J, Rose-John S.

J Clin Invest. 2011 Sep;121(9):3375-83. doi: 10.1172/JCI57158. Epub 2011 Sep 1. Review.

15.

Signal transduction of IL-6, leukemia-inhibitory factor, and oncostatin M: structural receptor requirements for signal attenuation.

Anhuf D, Weissenbach M, Schmitz J, Sobota R, Hermanns HM, Radtke S, Linnemann S, Behrmann I, Heinrich PC, Schaper F.

J Immunol. 2000 Sep 1;165(5):2535-43.

16.

Clinical studies in patients with Castleman's disease, Crohn's disease, and rheumatoid arthritis in Japan.

Nishimoto N.

Clin Rev Allergy Immunol. 2005 Jun;28(3):221-30. Review.

PMID:
16129906
17.

IL-6: from its discovery to clinical applications.

Kishimoto T.

Int Immunol. 2010 May;22(5):347-52. doi: 10.1093/intimm/dxq030. Epub 2010 Apr 21. Review.

18.

IL-6 cytokine family and signal transduction: a model of the cytokine system.

Hibi M, Nakajima K, Hirano T.

J Mol Med (Berl). 1996 Jan;74(1):1-12. Review.

PMID:
8834766
19.

Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes.

Kurth I, Horsten U, Pflanz S, Dahmen H, Küster A, Grötzinger J, Heinrich PC, Müller-Newen G.

J Immunol. 1999 Feb 1;162(3):1480-7.

20.

Immunotherapeutic implication of IL-6 blockade.

Tanaka T, Kishimoto T.

Immunotherapy. 2012 Jan;4(1):87-105. doi: 10.2217/imt.11.147. Review.

PMID:
22150003
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk